QUOTE AND NEWS
newratings.com  Dec 8  Comment 
PARIS (dpa-AFX) - Arena Pharmaceuticals Inc. (ARNA) has completed enrollment in its phase II trial of Ralinepag for the treatment of pulmonary arterial hypertension, with about 60 patients. The company expects to report results from this study...
newratings.com  Dec 8  Comment 
PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNY) announced Thursday that the European Medicines Agency or EMA has accepted for review the Marketing Authorization Application for Dupixent (dupilumab) for the treatment of...
Motley Fool  Dec 5  Comment 
Shares rallied in response to the general uptick in the biotech sector and a string of positive announcements.
Motley Fool  Dec 2  Comment 
Regeneron CEO Leonard Schleifer thinks that biopharma needs to focus more on innovation and less on pricing for future growth if it wants to restore credibility with payers, patients, and politicians.
Benzinga  Nov 30  Comment 
Kyle Dennis, co-founder of biotechbreakouts.com, recently joined PreMarket Prep to share his thoughts on Opthotech Corp (NASDAQ: OPHT). According to Dennis, Opthotech will either be a huge hit or miss for traders within the next month. The...
Benzinga  Nov 21  Comment 
On Friday, the Vetr crowd upgraded their rating of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) from 4 stars (buy), issued two days ago, to 4.5 stars (strong buy). Expectation for the stock is high with 83 percent of user ratings...
Motley Fool  Nov 18  Comment 
Which of these two beaten-down drug stocks is better poised for a rebound: Regeneron or Novartis?
Motley Fool  Nov 8  Comment 
Two disappointing updates caused shares to tumble.
newratings.com  Nov 4  Comment 
WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for its third quarter that advanced from last year. The company said its bottom line totaled $365 million, or $3.13 per share. This was up from $276 million, or $2.38 per...




RELATED WIKI ARTICLES
 
TOP CONTRIBUTORS

Since its inception in 1988, Regeneron Pharmaceuticals, Inc. (REGN) has operated as a research and development (R&D) company engaged in the development of drugs for the treatment of various diseases. Regeneron's goal is to become a fully integrated biopharmaceutical company by commercializing these drugs. The company has advanced a few of its pipeline drugs into clinical stage development. The leading drug programs in this regard are IL-1, for inflamatory disease, and VEGF, for cancer and eye diseases. Revenues consist of R&D collaboration payments from development partner Sanofi-Aventis and contract manufacturing payments from pharmaceutical giant Merck for a pediatric vaccine. Manufacturing agreement expired in October 2006. From 2007, revenue will mainly derive from collaboration with Sanofi-Aventis and Bayer and from technology transfers.

Regeneron is cururently based in Tarrytown, NY. In December 2006, the company signed a 15-year lease with BioMed Realty Trust, Inc. for a new corporate headquarters and research and development complex to be constructed adjacent to its current facility at the Landmark at Eastview in the Town of Greenburgh in Westchester County, New York. Regeneron also has the option to extend the lease for three additional 5-year periods. The new facilities will be constructed by BioMed Realty Trust over the next two years.

The Platform Techonology

Regeneron's most important propriatary technology is Trap Technology utilizing engineered antibody techniques. The decoy receptors (Traps) are composed of fusions between two distinct receptor components and a portion of an antibody molecule called the "Fc region", resulting in the generation of blockers with markedly increased affinity over that offered by single component reagents. Regeneron has applied this proprietary Trap technology to create a number of therapeutic candidates such as the IL-1 Trap and the VEGF Trap. The company also developed Velocigene/VelocImmune Technology which allows custom and precise manipulation of very large sequences of DNA to produce a highly customized knock-out of a specified target gene and accelerates the production of knock-out and transgenic expression models without using either positive/negative selection or isogenic DNA.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki